Monthly Archives: May 2011

Price Decline Equals Dividends Canceled

The question of retaining profits on quality dividend companies through the selling of a position seems to counter the whole point of dividend investing. After all, aren’t you supposed to allow the dividends to compound? In a small way, we described one approach and our rational for selling quality companies after small gains in yesterday’s article (Our Primary Concern: Retaining Profits).

However, there is another way to view the rationale behind selling a dividend stock after a “fair profit.”  In the early years of the Dow Theory Letters, Richard Russell would often cite a Robert Rhea quote about the impact of a stock decline.  Rhea said: 

“’Buying in bear markets is merely gambling and not very good gambling at that. Why not have cash instead of investments in bear markets? Why insist that one cannot afford to forego investment income when one day’s price shrinkage may cancel several years’ dividends?’”
Russell, Richard. Dow Theory Letter. May 10, 1960. Issue 103. page 2. www.dowtheoryletters.com.
The idea of canceling several years of dividends is at the forefront of our thinking when gains evaporate into losses.  In Richard Russell’s Dow Theory Letter dated November 23, 1960, he presents, in literal terms, the impact of price decline and the loss of years of dividend income in the process.  The table below is from Russell’s newsletter and needs little in the way of explanation.
Source: Richard Russell, Dow Theory Letters, http://www.dowtheoryletters.com/

Because stocks are not required to return principal with a stated yield as with many bonds, there is no assurance that the price will recover to the level that a purchase was initiated. Therefore, receiving short-term income on a dividend stock, although a necessary source of income for retired individuals, the prospect exists that an investor could end up with only a portion of the principal instead of the intended income plus principal.

The lack of assurance of principal and income with dividend stocks is why we believe people have become disenfranchised with technology stocks like Microsoft (MSFT) and Cisco Systems (CSCO).  If they’ve invested in the stocks with the belief that they’re in it forever, when the decline comes, absent any dividend, there is little recourse or hope of recovering lost funds or keeping up with inflation.

Even new investors to Microsoft and Cisco Systems, aware of their bold promises in 1999 and subsequent failure to deliver in 2011, are asking themselves, “is it really worth facing the prospect of no return?”  These questions are being asked when in some instances, especially with Microsoft, the timing probably couldn’t be better (especially now that they’re paying a dividend).  Our supplementary comments on Microsoft can be found here.

While we subscribe to the Graham/Buffett principles of investing (buying for the long-term, you’re buying a business, concentrate on values, etc.) we assume that since there are only a handful of billionaires hewn strictly from investing in stocks, we might do well to hedge our thinking and strategy.

Finally, further analysis of Robert Rhea’s claim on not being invested at all during bear markets is something that is at odds with Charles Dow and we’ve decided is not appropriate or necessary.  From our experience, bear markets are no guarantee of losses in your portfolio.  Charles H. Dow, founder of the Wall Street Journal, has said that:

"Even in a bear market, this method of trading will usually be found safe, although the profits taken should be less because of the liability of weak spots breaking out and checking the general rise."

Schultz, Harry D., A Treasury of Wall Street Wisdom, Investors' Press, (New Jersey, 1966). p. 12. Additional commentary here.

Evidence of the fact that bear markets don’t always equal destruction of wealth, while going long stocks, is demonstrated in our 2007, 2008 and 2009 performance review.  Naturally, 2008 is not expected to be replicated (having gains, while going long only, during a market decline of 40% or more).  However, we do know that being all in or timing the market to be all out during bear markets shouldn’t be the goal.  The goal, from our perspective, should be the preservation of gains whenever possible.

Please revisit New Low Observer for edits and revisions to this post.

The Jesse James of the Investment Industry?

It has been brought to our attention that the money belonging to the clients and shareholders of Glickenhaus & Co. hasn’t been treated well lately. In fact, the heir apparent to the Glickenhaus business has used client and shareholder money to finance his masters degree in reverse mergers, shell companies and organic “fertilizer.”

Apparently, 29-year old Jesse Glickenhaus wanted to bring the family firm into the modern era by investing in concepts like global warming and China. Unfortunately, the grandson of founder and senior partner SethGlickenhaus, is ahead of his time because the modern era of investing that he wished to introduce to his firm hasn’t arrived.

Jesse bought shares of fertilizer company China Agritech (CAGC) on the seemingly hot tip that Carlyle Group was already up to their armpits in the “stuff.” As well connected as the Carlyle Group is with a network of former heads of state and CEOs, how could you lose?

Being unclear what a shell company is, Jesse decided to dump $4 million dollars into China Agritech (CAGC). Well, as blind luck often works, not even six months after his investment, Jesse Glickenhaus found his shares to be worth approximately half of its initial value. To top it all off, the shares in organic “fertilizer” have been halted on the stock exchange since March 14, 2011.

To the relief of Jesse, having a family money management firm with $1.3 billion of assets under management makes a $2 million dollar loss seem like nothing at all. So it comes as no surprise that Jesse would say, “It would be easy to walk away at this point.” In his usually affable way, Jesse tries to clarify the prior thought with a well rehearsed but poorly chosen remark, “It’s not nothing, but it’s not a big deal for us financially.” The New Low Team isn’t known for quality craftsmanship with words however, we don’t think that such a flippant remark speaks well of the future holdings of Glickenhaus & Co.

With his education complete, Jesse has a new spring in his step and many lessons learned from his experience. What exactly did you learn, Jesse? “In the future, if I find a company in China, I’ll probably stick to those that have had a major, well-known auditor for several years. I learned it’s not that difficult to manipulate the market in a small-cap, publicly traded Chinese company.” Hmmm…that doesn’t sound all that unfamiliar to the methodology applied to China Agritech. Find a well-known company like Carlyle Group that already owned 22% of ChinaAgritech and jump right in.

What really brought down the share of China Agritech? According to Jesse, it was the short sellers. Short sellers are those curmudgeons who hate all that there is to do with free enterprise in the land of opportunity. We’re not sure who the opportunity is for in China, but we’re starting to get the picture. Jesse didn’t say anything about his breadth of knowledge on the topic of shell company listings in the U.S. Neither did he mention being the least bit perturbed that his “investment” has somehow become a sunk cost.

Things got so far out of hand that Jesse’s dad, James Glickenhaus, had to go to China to prove to himself that his son’s investment acumen hasn’t faltered in any way. Sure enough, James was able to confirm that his son is still very special, thank you for asking. James told the short selling neighbors next door to mind their own business and that his son is the best kid on the block by posting on YouTube a defense of his one time visit to the factories in China.

Dad, ever faithful to his son, went on to say that “[China Agritech] management has acted incompetently, there’s no question about it.” Somehow, dad was able to overlook the fact that if the executives of CAGC are inept then the conclusion should be that the investment decision wasn’t so hot either.

We’re not sure how dad’s visit will change the fact that China Agritech (CAGC) cannot be bought or sold since March 11th. Even those cantankerous short sellers can’t exploit poor ol’ CAGC. Stupid rule enforcement, prompted by the shorts, of the SEC and NASDAQ cut off the inevitable rise in the price of the stock.

In the glib fashion that Glickenhaus & Co. is famous for, dad says, “like sending him [Jesse] to business school.” Not to be outdone, Jesse closes with these parting thoughts, “I went into this with an open mind, I didn’t expect to enjoy it as much as I have.”

If the shareholders and clients of Glickenhaus & Co. aren’t somewhat alarmed at the on-record comments made by father and son, Jesse & James, then there should be little surprise at the potential underperformance of the invested funds going forward.

Please revisit New Low Observer for edits and revisions to this post. Email us.

Our Primary Concern: Retaining Profits

We have frequently claimed that our goal was never to have trading strategy while dealing with dividend paying stocks.  In fact, the whole purpose of mining the field of dividend stocks is to increase the odds that we can compound our investment income.
However, a recent example reminds us of the importance of being cognizant that “good” stock selecting isn’t enough.  Adherence to Charles H. Dow’s concept of recognizing values and seeking fair profits is critical to long-term success in the stock market.
In the article titled “When Timing Meets Opportunity,” we’ve outlined the importance of timing when selecting stocks.  That article demonstrated that a focus on stocks near a new one-year low was about as good as any time for starting investment research.  Stocks at a new low represent the best marker for determining values.  Keep in mind that our focus is on stocks that increase their dividend every year or members of the Nasdaq 100.  Thereafter, an individual would need to run through whichever fundamental and technical analysis necessary to make a decision that seems appropriate.  Our philosophy is to consider our portfolio allocation based on what Dow Theory indicates.  If we’re in a bull market we have a higher concentration in a single stock.  If we’re in a bear market then we have lower concentration in a single stock. In general, this addresses the “value” component according to Charles H. Dow.
The aspect regarding seeking fair profits, another Charles Dow tenet, was outlined in our article titled “Seeking Fair Profits in Investment Portfolios.”  That article specifically references quotes by Charles Dow regarding when to take a profit on a stock.  Strangely, Dow recommended taking “fair profits” of 5%.  The New Low Observer Team is a little more adventurous since we seek 10% or more.  However, the point remains that as investors we need to put our expectations in perspective before we commit our money.  Not after we’re stuck with large gains or losses.
A recent example that we have come across is the case of Northern Trust (NTRS).  Northern Trust (NTRS) typifies what usually happens to a well-timed play on values when the appreciation for “fair profits” isn’t understood.  Northern Trust was recommended on September 1, 2010.  This was almost literally at the one year low from the period of September 1, 2009 to September 1, 2010.
After receiving “only” 10.96% in a period of 64 days, we issued a Sell recommendation on Northern Trust (NTRS) feeling that an annualized gain of nearly 40% wasn’t worth quibbling about.  In the sell recommendation, we indicated that we expected the upside target to be first $56 and thereafter $59.  Almost as impossible as it seems, Northern Trust peaked at $56.86 and turned down from there.  Nearly 7 months on, Northern Trust (NTRS) has ranged from a 19% gains to the current 4%. In addition, this represents a loss of nearly half of the gain that was generated at the time of our sell recommendation.
The situation with Northern Trust typifies our experience and observation when investing in dividend increasing stocks.  Great companies with considerable qualitative elements rise for a moment and revert back to their prior low for inexplicable reasons.  In regards to the general ebb and flow of individual stocks, we’re primarily concerned with accepting what is reasonable and fair rather than what we typically want which is usually for the stock to got back to the previous one-year high.
As rudimentary as it seems, we feel that an understanding of values and seeking fair profits, as espoused by Charles Dow, is essential to long-term success in the stock market.
Please revisit New Low Observer for edits and revisions to this post. Email us.

Teva Pharmaceuticals (TEVA) Now Slated to Acquire Cephalon (CEPH)

The plot thickens with news that Teva Pharmaceuticals (TEVA) is going to buy Cephalon (CEPH) for $81.50 (article here).  Teva’s offer exceeds Valeant Pharmaceuticals’ (VRX) previous bid of $73. 

We originally recommended Cephalon (CEPH) in August of 2009.  After our August 2009 recommendation of Cephalon, we recommended selling the stock near the high of $71 in March 2010 before the decline to $56.  In February 2011 we recommended readers consider Cephalon at the $58 level.  From there the stock has appreciated 39% in less than 3 months.  The most recent run of Cephalon was followed by a sell recommendation on March 30, 2011 at slightly above $75.  We wagered that despite the prospect of getting a sweetened offer closer to the true value of the company, we didn’t need to argue with a nearly 200% annualized return.

Our recent recommendation of Teva Pharmaceuticals (TEVA) on April 5, 2011 puts a twist on our selling of Cephalon.  It has been reported that Cephalon’s board rejected the Valeant offer and has already accepted the Teva offer. 

Interestingly, both Teva Pharmaceuticals and Valeant Pharmaceuticals got a boost in their share price at the announcement of the acquisition of Cephalon.  Typically, the acquiring company shares would decline at the announcement of a major purchase.  This seems to indicates that the market recognizes the positive impact that Cephalon will have on the ultimate acquirer.

Investors seeking the qualitative elements of Cephalon but cannot justify the purchase at the current price can hedge their bets by buying Teva at the current undervalued levels and gain the growth prospects clout of both companies. Obviously, this assumes that the deal goes through between TEVA and CEPH. If the deal with Teva and Cephalon doesn’t go through, we still believe that Teva represents a solid value at the current price. 

 

Please revisit New Low Observer for edits and revisions to this post. Email us.

Nasdaq 100 Watch List: April 29, 2011

Below are the Nasdaq 100 companies that are within 19% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models. Although these companies are very risky, they provide significant opportunity to outperform the market in the coming year.

Symbol Name Price P/E EPS Yield P/B % from Low
AKAM Akamai Tech. 34.43 38.09 0.9 - 2.99 1.41%
TEVA Teva Pharma. 45.73 12.48 3.66 1.90% 1.89 1.94%
CSCO Cisco Systems 17.52 13.25 1.32 1.40% 2.1 6.05%
URBN Urban Outfitters 31.47 19.67 1.6 - 3.71 8.41%
MRVL Marvell Tech. 15.43 11.51 1.34 - 1.89 11.21%
AMGN Amgen Inc. 56.85 11.82 4.81 - 2.13 13.11%
ATVI Activision Blizzard 11.38 34.48 0.33 1.40% 1.34 13.91%
MSFT Microsoft 25.92 11.06 2.34 2.50% 4.63 14.03%
RIMM RIMM 48.65 7.67 6.34 - 3.3 14.39%
APOL Apollo Grp 40.03 15.07 2.66 - 4.34 18.61%

Watch List Summary

The deck has been reshuffled since our last Nasdaq list from April 15th.  New to our list are RIMM (RIMM) and Activision (ATVI).  There are five companies that are no long on our watch list.  Those five companies are Intel (INTC), Staples (SPLS), Infosys (INFY), Celgene (CELG) and Qiagen (QGEN).  Are these the next over-performing stocks for the coming year?  We're not sure but, technically speaking, the downside targets for these stocks are as follows:
  • QGEN-$17
  • INTC-$12
  • SPLS-$18
  • CELG-$48
  • INFY-$62

If you can handle the downside risk, then these might be opportune purchases.

Watch List Performance Review

The companies on our Watch List from a year ago did not hammer out any kind of investment performance to speak of.  Only two of the six companies did well, Qualcomm (QCOM) which rose 48.86% and Genzyme (GENZ) which got bought by SanofiAventis (SNY) for $74 a share.  As a group, the average gain was only 6.81% while the Nasdaq 100 Index rose 15.67% in the same one year period.

Symbol Name 4/24/2010 4/24/2011
% change
GILD Gilead Sciences 41.67 39.06
-6.26%
QCOM QUALCOMM 38.25 56.94
48.86%
GENZ Genzyme Corp 53.93 74.00
37.21%
ATVI Activision Blizzard 11.60 11.32
-2.41%
RYAAY Ryanair Holdings 29.19 29.43
0.82%
APOL Apollo Group 63.53 39.80
-37.35%
- - - Average
6.81%
^NDX Nasdaq 100 Index 2055.33 2377.3
15.67%

Please revisit New Low Observer for edits and revisions to this post. Email us.